Literature DB >> 3951791

Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients.

T Hajto, C Lanzrein.   

Abstract

20 breast cancer patients received a single intravenous infusion of Iscador, a mistletoe (Viscum album L.) extract. Natural killer (NK) and antibody-dependent cell-mediated cytotoxicity (ADCC) activities as well as the number of large granular lymphocytes (LGL) were investigated in their peripheral blood at various times. Six hours after the start of the infusion, significant decreases and 24 h later, significant increases in NK/ADCC activities and LGL frequencies were observed. These responses followed a kinetic pattern similar to that which has been described by others to occur after treatment with interferon.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3951791     DOI: 10.1159/000226342

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

Review 1.  Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-05-05       Impact factor: 8.262

2.  Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.

Authors:  G Stein; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo.

Authors:  Lucie Heinzerling; Volker von Baehr; Christa Liebenthal; Rüdiger von Baehr; Hans-Dieter Volk
Journal:  J Clin Immunol       Date:  2006-05-17       Impact factor: 8.317

4.  Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells.

Authors:  Soo Jung Lee; Young-Ok Son; Hyunjin Kim; Joo-Young Kim; Soon-Won Park; Jae-Ho Bae; Hyung Hoi Kim; Eun-Yup Lee; Byung-Seon Chung; Sun-Hee Kim; Chi-Dug Kang
Journal:  J Clin Immunol       Date:  2007-05-25       Impact factor: 8.317

5.  NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Authors:  Patrick J Mansky; Dawn B Wallerstedt; Timothy S Sannes; Jamie Stagl; Laura Lee Johnson; Marc R Blackman; Jean L Grem; Sandra M Swain; Brian P Monahan
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-27       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.